More Than Fat in the Liver: The Metabolic Burden of Excess Adiposity

Description:

Hear from leading experts in the field and explore the evolving understanding of obesity as a chronic disease and its impact on the digestive system. This two-part program explores the prevalence and clinical staging of metabolic dysfunction-associate steatoic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) in the general population.

Part 1: Expert panel lecture

Our panel delivers a comprehensive overview of the latest practical guidance on the diagnostic evaluation, evidence-based management, and strategies to improve patient outcomes. Topics include: 

• Understanding how the diagnosis of obesity has evolved over time and how it may affect the digestive tract including the liver.   
• Defining prevalence and clinical staging of MASLD/MASH in the general population.   
• Practical approaches to diagnostic evaluation and management of this common condition. 

Part 2: Product Theater sponsored by Boehringer Ingelheim

Presented by Nadege Gunn, MD, CPI, DABOM, FAASLD, this session spotlights obesity as a chronic disease that affects the whole body, not just weight, and places a heavy burden on the body. Topics include: 

• Obesity is not a secondary issue but a central, modifiable risk factor for MASLD/MASH progression, fibrosis, and downstream liver outcomes. 
• Reinforcement that MASLD/MASH is common, often silent, and underdiagnosed, and that gastroenterologists play a critical role in identifying patients earlier using noninvasive tools like FIB‑4. 
• Effective weight management and how it can meaningfully improve liver disease, cardiometabolic risk, and long‑term patient outcomes.